Levofloxacin Kabi (Levofloxacin)

• Levofloxacin Kabi is a fluoroquinolone antibiotic used to treat bacterial infections in several organ systems.
• Community‑acquired pneumonia: provides bactericidal activity against common respiratory pathogens, improving clinical outcomes.
• Acute bacterial sinusitis: reduces sinus inflammation by eradicating susceptible bacterial strains.
• Skin and soft‑tissue infections: eliminates Gram‑negative and Gram‑positive organisms causing cellulitis, abscesses, and wound infections.
• Complicated urinary tract infections: achieves high urinary concentrations to treat resistant Enterobacteriaceae and other uropathogens.
• Intra‑abdominal infections: effective against mixed aerobic and anaerobic bacteria when used in combination therapy.

• Levofloxacin exerts its antibacterial effect by binding to the A subunits of bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. This inhibition prevents the supercoiling and relaxation of DNA required for replication and transcription, leading to rapid bacterial cell death. The drug displays concentration‑dependent killing and a post‑antibiotic effect against a broad spectrum of Gram‑negative and Gram‑positive organisms.

Levofloxacin Kabi may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild gastrointestinal upset occurring in many patients.
• Diarrhea: loose stools that are usually self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: sensation of light‑headedness or imbalance.

Serious or Rare Side Effects

• Tendon rupture: sudden tendon pain or rupture, especially in the Achilles.
• QT interval prolongation: cardiac rhythm disturbances that may lead to arrhythmia.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile‑associated diarrhea: severe colitis requiring medical intervention.

Prior to initiating Levofloxacin Kabi, clinicians should evaluate several patient‑specific factors to minimize risk.

• Renal function: assess creatinine clearance and adjust dose in patients with impaired renal function.
• History of tendon disorders: avoid use in individuals with prior tendon injury or those on corticosteroids.
• Cardiac risk: monitor QT interval in patients with known prolongation or electrolyte abnormalities.
• Concomitant CNS‑active drugs: use caution when combined with agents that lower seizure threshold.
• Pregnancy and lactation: safety not established; prescribe only if potential benefit outweighs risk.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levofloxacin Kabi can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: markedly reduce levofloxacin absorption.
• Warfarin: potentiate anticoagulant effect, increasing bleeding risk.
• Theophylline: inhibit metabolism leading to elevated plasma concentrations.
• Cyclosporine: increase risk of neurotoxic adverse events.

Moderate Interactions (Monitor Closely)

• NSAIDs: may enhance central nervous system toxicity.
• Corticosteroids: raise likelihood of tendon rupture.
• Diabetes medications (e.g., insulin, oral hypoglycemics): may affect glucose control.